250 related articles for article (PubMed ID: 11114131)
1. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens.
Rossini F; Verga M; Pioltelli P; Giltri G; Sancassani V; Pogliani EM; Corneo G
Haematologica; 2000 Dec; 85(12):1255-60. PubMed ID: 11114131
[TBL] [Abstract][Full Text] [Related]
2. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
3. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution.
Specchia G; Pastore D; Carluccio P; Mele G; Montagna MT; Liso A; Rizzi R; Ianora AS; Liso V
Leuk Lymphoma; 2003 Jan; 44(1):97-101. PubMed ID: 12691147
[TBL] [Abstract][Full Text] [Related]
4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
5. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
[TBL] [Abstract][Full Text] [Related]
6. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
[TBL] [Abstract][Full Text] [Related]
8. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
9. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
11. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
14. Outcome of biphenotypic acute leukemia.
Killick S; Matutes E; Powles RL; Hamblin M; Swansbury J; Treleaven JG; Zomas A; Atra A; Catovsky D
Haematologica; 1999 Aug; 84(8):699-706. PubMed ID: 10457405
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of early treatment response in children with acute myeloid leukemia].
Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
[TBL] [Abstract][Full Text] [Related]
16. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
17. The benefit of induction chemotherapy in patients age > or = 75 years.
Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
[TBL] [Abstract][Full Text] [Related]
18. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
